Because sunitinib is currently FDA-approved to treat renal cell carcinoma, we believe that testing recombinant IFN-γ in conjunction with this drug would be worthwhile, with the goal of increasing response rates with low risk of additional toxicity. The gene discussed is IFNG; the disease is renal cell carcinoma.